NCT07037758View on ClinicalTrials.gov

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

PHASE1RecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

March 4, 2028

Study Completion Date

January 4, 2031

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

Tarlatamab

Administered as an IV infusion.

DRUG

AB248

Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.

Trial Locations (4)

38120

RECRUITING

Baptist Cancer Center, Memphis

40202-1703

RECRUITING

Norton Cancer Institute - Downtown, Louisville

06230

RECRUITING

Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara

06800

RECRUITING

Ankara Bilkent Sehir Hastanesi, Ankara

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
collaborator

Asher Biotherapeutics, Inc.

INDUSTRY

lead

Amgen

INDUSTRY